Venus Concept Inc.
Toronto, Ontario, Canada · Biotechnology, Consumer Goods, Cyber Security
Venus Concept, A Global Leader In The Medical Aesthetics Industry We use cutting-edge technology to develop safe, non-invasive & minimally invasive devices that address today's most in-demand aesthetic needs. As a leading medical aesthetic device company, we are currently present in over 60 countries and 29 direct markets with more than 10 million Venus Concept treatments performed worldwide an
Key facts
- Headquarters
- Toronto, Ontario, Canada
- Employees
- 300
- Industries
- Biotechnology, Consumer Goods, Cyber Security
- Status
- Private
- Website
- https://www.venusconcept.com
- Company page
Recent activity at Venus Concept Inc.
- : Venus Concept
- : SEC 8-K (1.01): On January 29, 2026, Venus Concept Inc. and its subsidiaries entered into a Consent Agreement with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP. This agreement waives certain minimum liquidity requirements under the existing Main Street Priority Loan Agreement until February 13, 2026, and allows for the payment of interest to be applied to outstanding principal balances. Additionally, on the same day, a Twenty Fifth Bridge Loan Amendment was made to extend the maturity date of a bridge loan from January 31, 2026 to February 13, 2026, while also increasing the delayed draw commitment from $26 million to $28 million. These agreements are significant as they provide financial relief and flexibility to the Company during a critical period.
- : SEC 8-K (1.01):
- : SEC 8-K (1.01): On December 31, 2025, Venus Concept Inc. and its subsidiaries entered into a Consent Agreement with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP, which waived certain minimum liquidity requirements under the MSLP Loan Agreement until January 14, 2026. Additionally, the Loan Parties executed the Twenty Third Bridge Loan Amendment, extending the maturity date of a prior Bridge Loan from December 31, 2025, to January 14, 2026, while also waiving specific liquidity requirements. These agreements are crucial for maintaining liquidity and financial stability for the Company through the upcoming financial obligations set for January 2026.
- : SEC 8-K (1.01): On November 30, 2025, Venus Concept Inc. and its subsidiaries entered into a Consent Agreement with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP. This agreement waives certain liquidity requirements under the existing Loan and Security Agreement, allowing Venus USA to apply a cash interest payment due on December 8, 2025, to the outstanding principal balance of the notes. Additionally, a Twenty Second Bridge Loan Amendment was executed on the same day, which extends the maturity date of an existing bridge loan from November 30, 2025, to December 31, 2025, and also waives certain liquidity requirements until the end of December 2025. These amendments provide Venus Concept with essential financial flexibility to manage their operations effectively during this period.
- : SEC 8-K (8.01): On November 10, 2025, the Company issued a press release announcing that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Venus Nova, a new multi-application platform designed for non-invasive body and skin treatments. This significant regulatory approval enables the Company to advance its product offerings in the aesthetics market, potentially enhancing its revenue streams. The press release, attached as Exhibit 99.2, includes forward-looking statements regarding the anticipated impact of the Venus Nova on the Company's market position and future financial performance. The clearance is an important milestone in the Company's development pipeline, reflecting its ongoing commitment to innovation in non-invasive treatments.
- : SEC 8-K (1.01): On October 31, 2025, Venus Concept Inc. and its subsidiaries entered into a Consent Agreement with Madryn Health Partners, granting relief under the MSLP Loan Agreement by waiving certain minimum liquidity requirements until November 30, 2025. Additionally, the parties executed a Twenty First Bridge Loan Amendment, extending the maturity date of the bridge loan from October 31, 2025 to November 30, 2025, and also waiving liquidity requirements through the same date. The agreements aim to provide the Company with necessary financial flexibility as it navigates its current obligations and interests, particularly involving cash interest payments due on November 8, 2025. The agreements reflect strategic maneuvers to optimize the Company's debt servicing and maintain operational stability.
- : SEC 8-K (1.01): On October 31, 2025, Venus Concept Inc. and its subsidiaries entered into a Consent Agreement with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP. This agreement provides relief under the existing Loan and Security Agreement dated December 8, 2020. The Loan Parties include Venus Concept USA, Inc., Venus Concept Canada Corp., and Venus Concept Ltd., indicating a coordinated effort among the subsidiaries to address lender requirements. This agreement may impact the company's financial obligations, as it relates to significant funding arrangements.
- : Venus Concept Announces $11 million Debt-to-Equity Exchange Transaction with Madryn Asset Management, LP
- : Venus Concept Expands International Distribution Network and Certifies Products in India
Venus Concept Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2026 | Venture | $1.5M |
| Mar 2024 | Seed | $1.1M |
| May 2023 | Seed | $2.0M |
| Nov 2022 | Venture | $6.7M |
| Dec 2021 | Seed | $4.7M |
Leadership
- Keith Sullivan, Director
- Domenic Serafino, Executive Officer, Director
- Scott Barry, Director
- Garheng Kong, Director
- Louise Lacchin, Director
- Fritz LaPorte, Director
- Anthony Natale, Director
- Keith Sullivan, Director
- Frederic Moll, Director
- Keith Sullivan, Director
- Anthony Natale, Director
- Fritz LaPorte, Director
Verified email and direct lines for Venus Concept Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Venus Concept Inc. in the news
Companies similar to Venus Concept Inc.
- Aclarion · Biotechnology, Healthcare, Health Care, Other
- ROM Technologies · Healthcare, Health Care, Other
- Nurix Therapeutics · Biotechnology, Health Care, Other
- Dashlane · Cyber Security, Other, Security
- Harrow · Biotechnology, Healthcare, Health Care
About Venus Concept Inc.: questions and answers
What does Venus Concept Inc. do?
Venus Concept, A Global Leader In The Medical Aesthetics Industry We use cutting-edge technology to develop safe, non-invasive & minimally invasive devices that address today's most in-demand aesthetic needs. As a leading medical aesthetic device company, we are currently present in over 60 countries and 29 direct markets with more than 10 million Venus Concept treatments performed worldwide an
Where is Venus Concept Inc. headquartered?
Venus Concept Inc. is headquartered in Toronto, Ontario, Canada.
How many employees does Venus Concept Inc. have?
Venus Concept Inc. has about 300 employees.
Has Venus Concept Inc. raised funding?
Yes. Fundz has recorded 5 funding events for Venus Concept Inc.. The most recent, $1.5M, was in Apr 2026.
What is the latest news on Venus Concept Inc.?
On Apr 09, 2026, Venus Concept
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy